Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer

Autores
Knott, María Elena; Minatta, J.N; Roulet, L.; Gueglio G.; Pasik, Leonardo; Ranuncolo, Stella Maris; Nuñez, M; Puricelli, Lydia Ines; De Lorenzo, M
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: The finding of new biomarkers is needed to have a better sub-classification of primary renal tumors (RCC) as well as more reliable predictors of outcome and therapy response. In this study, we evaluated the role of circulating FGF21, an endocrine factor, as a diagnostic and prognostic biomarker for ccRCC.Materials and Methods: Serum samples from healthy controls (HC), clear cell and chromophobe RCC cancer patients were obtained from the serum biobank ?Biobanco Público de Muestras Séricas Oncológicas? (BPMSO)of the ?Instituto de Oncología ?Ángel H. Roffo?. Serum FGF21 and leptin were measured by ELISA while other metabolic markers were measured following routinely clinical procedures.Results: One of our major findings was that FGF21 levels were significantly increased in ccRCC patients compared with HC. Moreover, we showed an association between the increased serum FGF21 levels and theshorter disease free survival in a cohort of 98 ccRCC patients, after adjustment for other predictors of outcome.Conclusion: Our results suggest that higher FGF21 serum level is an independent prognostic biomarker, associated with worse free-disease survival.
Fil: Knott, María Elena. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Minatta, J.N. Hospital Italiano; Argentina
Fil: Roulet, L.. Hospital Italiano; Argentina
Fil: Gueglio G.. Hospital Italiano; Argentina
Fil: Pasik, Leonardo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: Ranuncolo, Stella Maris. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Nuñez, M. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Puricelli, Lydia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: De Lorenzo, M. New Jersey Medical School; Estados Unidos
Materia
SERUM FIBROBLAST GROWTH FACTOR 21
CLEAR CELL RENAL CELL CARCINOMA
PROGNOSIS BIOMARKER
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/51029
Acceder
id CONICETDig_cc74128d5751ccc965a25e9044475a24
oai_identifier_str oai:ri.conicet.gov.ar:11336/51029
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal CancerKnott, María ElenaMinatta, J.NRoulet, L.Gueglio G.Pasik, LeonardoRanuncolo, Stella MarisNuñez, MPuricelli, Lydia InesDe Lorenzo, MSERUM FIBROBLAST GROWTH FACTOR 21CLEAR CELL RENAL CELL CARCINOMAPROGNOSIS BIOMARKERhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background: The finding of new biomarkers is needed to have a better sub-classification of primary renal tumors (RCC) as well as more reliable predictors of outcome and therapy response. In this study, we evaluated the role of circulating FGF21, an endocrine factor, as a diagnostic and prognostic biomarker for ccRCC.Materials and Methods: Serum samples from healthy controls (HC), clear cell and chromophobe RCC cancer patients were obtained from the serum biobank ?Biobanco Público de Muestras Séricas Oncológicas? (BPMSO)of the ?Instituto de Oncología ?Ángel H. Roffo?. Serum FGF21 and leptin were measured by ELISA while other metabolic markers were measured following routinely clinical procedures.Results: One of our major findings was that FGF21 levels were significantly increased in ccRCC patients compared with HC. Moreover, we showed an association between the increased serum FGF21 levels and theshorter disease free survival in a cohort of 98 ccRCC patients, after adjustment for other predictors of outcome.Conclusion: Our results suggest that higher FGF21 serum level is an independent prognostic biomarker, associated with worse free-disease survival.Fil: Knott, María Elena. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Minatta, J.N. Hospital Italiano; ArgentinaFil: Roulet, L.. Hospital Italiano; ArgentinaFil: Gueglio G.. Hospital Italiano; ArgentinaFil: Pasik, Leonardo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; ArgentinaFil: Ranuncolo, Stella Maris. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Nuñez, M. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; ArgentinaFil: Puricelli, Lydia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; ArgentinaFil: De Lorenzo, M. New Jersey Medical School; Estados UnidosOmics International2016-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/51029Knott, María Elena; Minatta, J.N; Roulet, L.; Gueglio G.; Pasik, Leonardo; et al.; Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer; Omics International; Journal of Molecular Biomarkers & Diagnosis; S2; 15; 5-2016; 1-62155-9929CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4172/2155-9929.S2-015info:eu-repo/semantics/altIdentifier/url/https://www.omicsonline.org/open-access/circulating-fibroblast-growth-factor-21-fgf21-as-diagnostic-and-prognostic-biomarker-in-renal-cancer-2155-9929-S2-015.php?aid=73565info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:15:15Zoai:ri.conicet.gov.ar:11336/51029instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:15:15.576CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer
title Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer
spellingShingle Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer
Knott, María Elena
SERUM FIBROBLAST GROWTH FACTOR 21
CLEAR CELL RENAL CELL CARCINOMA
PROGNOSIS BIOMARKER
title_short Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer
title_full Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer
title_fullStr Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer
title_full_unstemmed Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer
title_sort Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer
dc.creator.none.fl_str_mv Knott, María Elena
Minatta, J.N
Roulet, L.
Gueglio G.
Pasik, Leonardo
Ranuncolo, Stella Maris
Nuñez, M
Puricelli, Lydia Ines
De Lorenzo, M
author Knott, María Elena
author_facet Knott, María Elena
Minatta, J.N
Roulet, L.
Gueglio G.
Pasik, Leonardo
Ranuncolo, Stella Maris
Nuñez, M
Puricelli, Lydia Ines
De Lorenzo, M
author_role author
author2 Minatta, J.N
Roulet, L.
Gueglio G.
Pasik, Leonardo
Ranuncolo, Stella Maris
Nuñez, M
Puricelli, Lydia Ines
De Lorenzo, M
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv SERUM FIBROBLAST GROWTH FACTOR 21
CLEAR CELL RENAL CELL CARCINOMA
PROGNOSIS BIOMARKER
topic SERUM FIBROBLAST GROWTH FACTOR 21
CLEAR CELL RENAL CELL CARCINOMA
PROGNOSIS BIOMARKER
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: The finding of new biomarkers is needed to have a better sub-classification of primary renal tumors (RCC) as well as more reliable predictors of outcome and therapy response. In this study, we evaluated the role of circulating FGF21, an endocrine factor, as a diagnostic and prognostic biomarker for ccRCC.Materials and Methods: Serum samples from healthy controls (HC), clear cell and chromophobe RCC cancer patients were obtained from the serum biobank ?Biobanco Público de Muestras Séricas Oncológicas? (BPMSO)of the ?Instituto de Oncología ?Ángel H. Roffo?. Serum FGF21 and leptin were measured by ELISA while other metabolic markers were measured following routinely clinical procedures.Results: One of our major findings was that FGF21 levels were significantly increased in ccRCC patients compared with HC. Moreover, we showed an association between the increased serum FGF21 levels and theshorter disease free survival in a cohort of 98 ccRCC patients, after adjustment for other predictors of outcome.Conclusion: Our results suggest that higher FGF21 serum level is an independent prognostic biomarker, associated with worse free-disease survival.
Fil: Knott, María Elena. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Minatta, J.N. Hospital Italiano; Argentina
Fil: Roulet, L.. Hospital Italiano; Argentina
Fil: Gueglio G.. Hospital Italiano; Argentina
Fil: Pasik, Leonardo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: Ranuncolo, Stella Maris. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Nuñez, M. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Puricelli, Lydia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: De Lorenzo, M. New Jersey Medical School; Estados Unidos
description Background: The finding of new biomarkers is needed to have a better sub-classification of primary renal tumors (RCC) as well as more reliable predictors of outcome and therapy response. In this study, we evaluated the role of circulating FGF21, an endocrine factor, as a diagnostic and prognostic biomarker for ccRCC.Materials and Methods: Serum samples from healthy controls (HC), clear cell and chromophobe RCC cancer patients were obtained from the serum biobank ?Biobanco Público de Muestras Séricas Oncológicas? (BPMSO)of the ?Instituto de Oncología ?Ángel H. Roffo?. Serum FGF21 and leptin were measured by ELISA while other metabolic markers were measured following routinely clinical procedures.Results: One of our major findings was that FGF21 levels were significantly increased in ccRCC patients compared with HC. Moreover, we showed an association between the increased serum FGF21 levels and theshorter disease free survival in a cohort of 98 ccRCC patients, after adjustment for other predictors of outcome.Conclusion: Our results suggest that higher FGF21 serum level is an independent prognostic biomarker, associated with worse free-disease survival.
publishDate 2016
dc.date.none.fl_str_mv 2016-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/51029
Knott, María Elena; Minatta, J.N; Roulet, L.; Gueglio G.; Pasik, Leonardo; et al.; Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer; Omics International; Journal of Molecular Biomarkers & Diagnosis; S2; 15; 5-2016; 1-6
2155-9929
CONICET Digital
CONICET
url http://hdl.handle.net/11336/51029
identifier_str_mv Knott, María Elena; Minatta, J.N; Roulet, L.; Gueglio G.; Pasik, Leonardo; et al.; Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer; Omics International; Journal of Molecular Biomarkers & Diagnosis; S2; 15; 5-2016; 1-6
2155-9929
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4172/2155-9929.S2-015
info:eu-repo/semantics/altIdentifier/url/https://www.omicsonline.org/open-access/circulating-fibroblast-growth-factor-21-fgf21-as-diagnostic-and-prognostic-biomarker-in-renal-cancer-2155-9929-S2-015.php?aid=73565
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Omics International
publisher.none.fl_str_mv Omics International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781583674048512
score 12.982451

Publicaciones similares